World Journal of Medical Microbiology

Journal profile

World Journal of Medical Microbiology(WJMR) is an international journal dedicated to the latest advancements in Medical Microbiology. The goal of this journal is to provide a platform for scientists and academicians all over the world to promote, share, and discuss various new issues and developments in different areas of Medical Microbiology.

Latest Articles

Open Access February 7, 2023 Endnote/Zotero/Mendeley (RIS) BibTeX

Relations between Dentistry and COVID-19 Infections

World Journal of Medical Microbiology 2023, 2(1), 22-26. DOI: 10.31586/wjmm.2023.609
Abstract
As a result of the virus's global dissemination, novel COVID-19 infections have emerged as a significant obstacle for all healthcare professionals to overcome. Dental specialist plays an effective role in the prevention of coronavirus. Dental care units and settings face various problems relating to the transmission of disease during treatment
[...] Read more.
As a result of the virus's global dissemination, novel COVID-19 infections have emerged as a significant obstacle for all healthcare professionals to overcome. Dental specialist plays an effective role in the prevention of coronavirus. Dental care units and settings face various problems relating to the transmission of disease during treatment and dental operations. Blood, saliva, and mixed water droplets possessing the virus cause contamination of equipment used for dental treatment. Both patients and workers may become transmitters and infectors of COVID-19 through direct contact during dental operations. Both dental workers and patients are likely to become infectors and transmitters of COVID-19. The dental care routine is very effective as we discussed below the prevention steps are very effective. All healthcare workers at the dentistry clinics, including nurses, should collaborate to prevent the spread of the COVID-19 virus among patients.Full article
Brief Review
Open Access January 28, 2023 Endnote/Zotero/Mendeley (RIS) BibTeX

Participation in the National Campaign on Viral Hepatitis C and Non-Communicable Diseases among Administrative Workers of Ain Shams University, Egypt

World Journal of Medical Microbiology 2023, 2(1), 14-21. DOI: 10.31586/wjmm.2023.584
Abstract
Background: On the first of October 2018, the Egyptian Ministry of Health and Population (MOHP) launched an initiative; named “100 Million Healthy Lives”, for nationwide screening of hepatitis c virus (HCV) and non-communicable diseases (NCDs). Egypt has the highest prevalence of HCV infection in the world where about 10% of
[...] Read more.
Background: On the first of October 2018, the Egyptian Ministry of Health and Population (MOHP) launched an initiative; named “100 Million Healthy Lives”, for nationwide screening of hepatitis c virus (HCV) and non-communicable diseases (NCDs). Egypt has the highest prevalence of HCV infection in the world where about 10% of the Egyptian population is affected by the disease. NCDs are the leading cause of mortality in Egypt and account for about 84% of all deaths. This study was conducted to a) Estimate the prevalence of participation in the national campaign on viral hepatitis C and non-communicable diseases among administrative workers in Ain shams University (ASU), b) Estimate the self-reported satisfaction of these participants with the campaign. Subjects and Methods: A cross-sectional study was conducted on 400 administrative workers of ASU faculties between March and August 2019 in Cairo, Egypt. A multistage random sample was done. Results: The study showed that 96% of the study group participated in the campaign. “Evaluating health status” was considered the main reason for participation at 92%, followed by "desire to obtain follow-up card", at 36%. Non-participation rate was about 4% and the main cause of non-participation was “fear of needle prick". About 91% of the participants were satisfied with the provided services. Mass media played a major role in awareness about the campaign for 91% of participants. Conclusions: The majority of the study group participated and was satisfied with the campaign. Mass media played a major role in participant awareness of the campaign.Full article
Figures
Article
Open Access January 3, 2023 Endnote/Zotero/Mendeley (RIS) BibTeX

Antibiotic prescriptions for COVID-19 patients increased during the BA.5 period

World Journal of Medical Microbiology 2023, 2(1), 11-13. DOI: 10.31586/wjmm.2023.579
Abstract
The initial omicron (B.1.1.529) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subvariants, BA.1 and BA.2 (BA.1/2), were progressively displaced by BA.5 in Japan, which showed not only higher transmittivity and less pathogenicity, but also differences in antibiotic use according to the difference in the clinical course of BA.5 compared with
[...] Read more.
The initial omicron (B.1.1.529) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) subvariants, BA.1 and BA.2 (BA.1/2), were progressively displaced by BA.5 in Japan, which showed not only higher transmittivity and less pathogenicity, but also differences in antibiotic use according to the difference in the clinical course of BA.5 compared with BA.1/2 infections. BA.5 patients received more antibiotics, especially ampicillin/sulbactam, although ceftriaxone and meropenem were used significantly in the BA.1/2 period. These data suggest an increased incidence of aspiration pneumonia in elderly patients in the BA.5 period, and we should consider changing the management tactics for COVID-19.Full article
Commentary
Open Access December 28, 2022 Endnote/Zotero/Mendeley (RIS) BibTeX

Epidemiological and Clinical Characteristics of COVID-19 Suspect Cases at the Triage of Ain Shams University Hospitals during the First Wave

World Journal of Medical Microbiology 2023, 2(1), 1-10. DOI: 10.31586/wjmm.2023.563
Abstract
Background: In December 2019, a cluster of patients with unexplained viral pneumonia was identified in Wuhan, China. Since March 11th 2020 the WHO declared COVID 19 as a pandemic with rising number of cases all over the world. Aim of the work: The aim of the study was to measure
[...] Read more.
Background: In December 2019, a cluster of patients with unexplained viral pneumonia was identified in Wuhan, China. Since March 11th 2020 the WHO declared COVID 19 as a pandemic with rising number of cases all over the world. Aim of the work: The aim of the study was to measure the percentages of possible, probable and provisionally excluded cases among the first 500 attendants of the triage of Ain Shams University Hospital and describe their epidemiological and clinical characteristics. Patients and Methods: This was a retrospective descriptive case series study including the first 500 patients attending the triage of Ain Shams University Hospitals from March 29th to May 31st. A constructed questionnaire in the form of a scoring system was used and data was collected through interviewing the patients after appropriate consent. Results: As regard the scoring system, 72.2% of patients had new onset of cough or old worsened cough in the previous 3 days, 59.2% had sore throat and 59% had dyspnea. Out of the 500 cases 33.2% were probable, 38.2% were possible and 28.2% were provisionally excluded. Conclusion: COVID-19 pneumonia usually occurred at an age younger than 47 years and it was more predominant in the male gender. The most common initial clinical presentations were new dry cough or chronic cough with worsening over the last 3 days, sore throat and/or runny nose and fever. Thirty-eight percent were classified as possible COVID-19 cases, and 33% were classified as probable.Full article
Figures
Article
Open Access October 25, 2022 Endnote/Zotero/Mendeley (RIS) BibTeX

Post COVID-19 Symptoms?

World Journal of Medical Microbiology 2022, 1(1), 32-34. DOI: 10.31586/wjmm.2022.478
Abstract
The SARS-COV-2 rapid spread caused an international public health emergency with unprecedented rates of morbidity and mortality. Post COVID-19 condition occurs as a spectrum of symptoms that present four or more weeks after acute infection with SARS-CoV-2. Most published data to date state 50-70% of hospitalized patients experienced at least
[...] Read more.
The SARS-COV-2 rapid spread caused an international public health emergency with unprecedented rates of morbidity and mortality. Post COVID-19 condition occurs as a spectrum of symptoms that present four or more weeks after acute infection with SARS-CoV-2. Most published data to date state 50-70% of hospitalized patients experienced at least one post-acute COVID-19 symptom up to 3 months after discharge. Commonly reported symptoms include; neurocognitive post COVID-19 (fatigue, dizziness, inattention, and brain fog), respiratory post-COVID (dyspnea, chest pain, and cough), and mental health related symptoms (insomnia, depression, and post-traumatic stress disorder). Additionally, gastro-intestinal post COVID-19 (diarrhea, vomiting, and abdominal pain) along with decline in quality of life and decreased ability to perform activities of daily living were reported. The response to post COVID-19 symptoms is still in its infancy despite being an emerging crisis as scientific evidence and robust data are nonetheless required for clear definition, identification of time frame, classification and management of the condition. New studies are needed to identify total and individual incidence/prevalence rates of different clinical presentations of post COVID-19 symptoms. These future studies will help us to o improve early recognition of long term symptoms after acute infection of COVID-19.Full article
Mini Review
Open Access October 25, 2022 Endnote/Zotero/Mendeley (RIS) BibTeX

Ivermectin for Treatment of COVID-19?

World Journal of Medical Microbiology 2022, 1(1), 30-31. DOI: 10.31586/wjmm.2022.474
Abstract
Many attempts have been made to repurpose existing and approved drugs for the treatment of COVID-19 infection. This involves anti-malarial drugs such as hydroxychloroquine and chloroquine, which have been shown to be less successful than initially believed, with a substantial risk of often fatal complications and interactions. This also involves
[...] Read more.
Many attempts have been made to repurpose existing and approved drugs for the treatment of COVID-19 infection. This involves anti-malarial drugs such as hydroxychloroquine and chloroquine, which have been shown to be less successful than initially believed, with a substantial risk of often fatal complications and interactions. This also involves Remdesivir, which has been shown to decrease recovery time significantly in hospitalized patients. However, for patients who are not yet hospitalized, there is no currently accepted treatment. Treating patients before they need to be admitted or even prophylactically could greatly decrease the load on hospitals, protect healthcare workers and reduce the spread of COVID-19. An in-vitro study indicated that Ivermectin was dynamic against COVID-19-infected cell. Ivermectin has antimicrobial, antiviral, and anticancer, immunomodulatory properties. This drug could reduce the viral load in COVID-9 infected patients, with potential effect on disease progression and spread. Therefore, Ivermectin may be a therapeutic choice for treatment of COVID-19, however, there is still a lack of evidence-based studies to support ivermectin treatment of patients with COVID-19.Full article
Opinion
Open Access October 24, 2022 Endnote/Zotero/Mendeley (RIS) BibTeX

Probiotics and Intestinal Microbiome: A Review of Literature

World Journal of Medical Microbiology 2022, 1(1), 25-29. DOI: 10.31586/wjmm.2022.479
Abstract
Probiotics, prebiotics, and synbiotics modify various aspects of local and systemic immune function in multiple experimental models. However, their impact and mechanisms of action are not known across all products or noticed in every population studied, and impacts on in vitro, ex vivo, or other measures of immune function do
[...] Read more.
Probiotics, prebiotics, and synbiotics modify various aspects of local and systemic immune function in multiple experimental models. However, their impact and mechanisms of action are not known across all products or noticed in every population studied, and impacts on in vitro, ex vivo, or other measures of immune function do not necessarily result in an impact on infection and illness in vivo. Studies have discussed that intestinal microbiota has an essential role in enhancing the immune system against viruses. The regulatory impact of the intestinal microbiota on viral infection is connected with local and systemic immune responses and plays a part in congenital and adaptive immune responses. The microbiota composition critically modulates the production of virus-specific CD4 and CD8 T cells and antibody responses following influenza virus infection. The intestinal microbiota has an important role in the stabilizing of immune homeostasis by augmenting the integrity of the barrier functions of the gut mucosa, which is a crucial aspect of systemic immunity. In conclusion, the intestinal microbiota can influence organismal immunity locally and systemically, proximally, and distally. Studying the possible mechanism by which the intestinal microbiota maintains host immunity can provide a clearer understanding of the occurrence and development of diseases.Full article
Essay
Open Access October 2, 2022 Endnote/Zotero/Mendeley (RIS) BibTeX

Thoughts on Pneumococcal Vaccination for the Adult Individuals with Autoimmune Diseases

World Journal of Medical Microbiology 2022, 1(1), 18-24. DOI: 10.31586/wjmm.2022.441
Abstract
Streptococcus pneumoniae is an important pathogenic bacteria causing pneumonia and invasive pneumococcal diseases, and the vaccination for pneumococcal vaccination is recommended in patients with RA and other autoimmune disorders. Compared with the immunocompetent individuals, frequency and the mortality rate were higher in the RA patients. The effect of pneumococcal vaccination
[...] Read more.
Streptococcus pneumoniae is an important pathogenic bacteria causing pneumonia and invasive pneumococcal diseases, and the vaccination for pneumococcal vaccination is recommended in patients with RA and other autoimmune disorders. Compared with the immunocompetent individuals, frequency and the mortality rate were higher in the RA patients. The effect of pneumococcal vaccination may not be weakened in people using corticosteroid and biological disease-modifying anti-rheumatic drug (DMARD) currently being used, but mild to relatively inhibition of immunogenicity was suggested in patients using either methotrexate or rituximab. Administration of 13-valent pneumococcal conjugate vaccine (PCV13), rather than 23-valent Pneumococcal polysaccharide vaccine (PPSV23) may be desirable in preventing pneumonia in people with autoimmune disease and sequential administration of PCV13 in people aged ≤64 years and PPSV23 from age ≥65 years may be useful for preventing pneumonia in people with autoimmune disease according to the insurance system. In addition, PCV15 and PCV 20 will be available soon and expected for more clinical efficiency rather than current PCV13 and PPSV23.Full article
Mini Review
Open Access September 12, 2022 Endnote/Zotero/Mendeley (RIS) BibTeX

Role of Probiotics for Treatment of Psoriasis?

World Journal of Medical Microbiology 2022, 1(1), 15-17. DOI: 10.31586/wjmm.2022.413
Abstract
Psoriasis is a multi-systemic chronic autoimmune inflammatory disorder affecting 125 million people worldwide. The most common type of psoriasis is plaque psoriasis affecting up to 90% of the patients and is characterized by well-demarcated, symmetric, and erythematous plaques with overlying silvery scales that may be painful or itchy. Psoriasis may
[...] Read more.
Psoriasis is a multi-systemic chronic autoimmune inflammatory disorder affecting 125 million people worldwide. The most common type of psoriasis is plaque psoriasis affecting up to 90% of the patients and is characterized by well-demarcated, symmetric, and erythematous plaques with overlying silvery scales that may be painful or itchy. Psoriasis may also affect the joints; increase the risk of developing metabolic syndrome, diabetes, Crohn’s disease, ulcerative colitis, uveitis, certain cancers and an increase in the risk of cardiovascular diseases. Both the skin and the gut microbiome can modulate the development and progression of psoriasis. A connection between the microbiome and immunological mechanisms are antimicrobial peptides, which regulate the microbiome at interfaces and, as antigens, can trigger psoriasis. Few studies were conducted to demonstrate the effect of probiotics on different diseases, as they are living microorganisms that confer a health benefit when administrated in adequate amounts. The effects of administering probiotics include the stabilization of the gut bacterial community and the restoration of “signature” of bacterial microbiota, which is a result of lowering the pH, producing bacteriocins, altering microRNA (miRNAs), competing with pathogens for certain nutrients and improving the gut barrier function. Probiotics counter weight aggressive commensals in the body and reinforce the barrier function of the epithelium while also contributing to the regulation of innate and adaptive immune responses of the host under healthy or pathogenic conditions. Several clinical trials were conducted based on those findings to examine the role of probiotics in psoriasis, but till now there is no evidence of their efficacy.Full article
Mini Review
Open Access August 4, 2022 Endnote/Zotero/Mendeley (RIS) BibTeX

Role of Probiotics in COVID-19 Management?

World Journal of Medical Microbiology 2022, 1(1), 13-14. DOI: 10.31586/wjmm.2022.372
Abstract
Probiotics as an intestinal microbe regulator, not only improve the ability of the gastrointestinal microbiota to modulate immune activity, but also strengthen the body's immune system, inhibit allergic reactions and has a significant role especially in the anti-viral immunomodulation. Therefore, in patients with COVID-19, the intestinal micro-eco-regulator, represented by probiotics,
[...] Read more.
Probiotics as an intestinal microbe regulator, not only improve the ability of the gastrointestinal microbiota to modulate immune activity, but also strengthen the body's immune system, inhibit allergic reactions and has a significant role especially in the anti-viral immunomodulation. Therefore, in patients with COVID-19, the intestinal micro-eco-regulator, represented by probiotics, may be a therapeutic choice. However, there is still a lack of evidence-based studies to support probiotic treatment of patients with COVID-19. New cohort studies and randomized controlled clinical trials to assess the effectiveness of probiotics in the management of COVID-19 are strongly and urgently needed.Full article
Opinion

Views of

Downloads of

Citations of

ISSN: 2836-4333
DOI prefix: 10.31586/wjmm
Journal metrics
Publication year
2021-2023
Journal (home page) visits
17777
Article views
10270
Article downloads
5081
Downloads/article
461.91
APC
free